Hematide analyse of EMERALD studies

Affymax, Inc. and Takeda Pharmaceutical Company Limited announced results of additional analyses from two Phase III studies (EMERALD 1 and 2) of the investigational agent, peginesatide (formerly known as Hematide) in chronic renal failure (CRF) patients on dialysis with anemia.The EMERALD studies, showed that once-monthly peginesatide was comparable to epoetin given up to 13 times a month in maintaining hemoglobin (Hb) levels with a generally similar adverse event rate.The new data providse additional information on the maintenance of Hb within treatment targets over time (up to 100 weeks), as well as cardiovascular safety results of this once-monthly agent in the dialysis patients studied. The companies plan to gfile at FDA in 2011.